205923-57-5

205923-57-5 structure

Name: Epratuzumab
Chemical Name: Lymphocide
CAS Number: 205923-57-5
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2018-07-13 15:29:47
Modify Date: 2025-08-25 12:25:06
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases[1].

Name	Lymphocide

Description	Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
In Vitro	Epratuzumab binds to CD22 ECD on Biacore with a KD of 0.7 nM, and resulting CD22 phosphorylation[1].Epratuzumab (0-100 μM; 1h) results in a dose dependent increase in CD22 internalization in Daudi lymphoma cells[1].
References	[1]. Carnahan J, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S.

No Any Chemical & Physical Properties